Gene Expression Profiling with DNA Microarrays: Advancing Our Understanding of Psychiatric Disorders

[1]  B. Dean,et al.  Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia , 2005, Journal of Neural Transmission.

[2]  C. Ross,et al.  Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. , 2003, Human molecular genetics.

[3]  J. Trojanowski,et al.  Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. , 2002, Archives of general psychiatry.

[4]  B. Devlin,et al.  Association and linkage analyses of RGS4 polymorphisms in schizophrenia. , 2002, Human molecular genetics.

[5]  Peter B. Jones,et al.  Gene expression analysis in schizophrenia: Reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Pierri,et al.  Gene Expression Profiling Reveals Alterations of Specific Metabolic Pathways in Schizophrenia , 2002, The Journal of Neuroscience.

[7]  Ji Huang,et al.  [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.

[8]  K. Mirnics.  Microarrays in brain research: Data quality and limitations , 2002 .

[9]  Desmond J. Smith.  Chips for Brains , 2002 .

[10]  H. Dohlman.  Regulators of G Protein Signaling (RGS Proteins) , 2002 .

[11]  J. Lieberman,et al.  Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. , 2002, The American journal of psychiatry.

[12]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[13]  H. Volz,et al.  Cell-mediated Side Effects of Psychopharmacological Treatment , 2001, Arzneimittelforschung.

[14]  S. Ludwin,et al.  Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions , 2001, Journal of Neuroimmunology.

[15]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[16]  J. Pevsner,et al.  Postmortem brain abnormalities of the glutamate neurotransmitter system in autism , 2001, Neurology.

[17]  B. Pollock,et al.  CYP2D6 Genotyping with Oligonucleotide Microarrays and Nortriptyline Concentrations in Geriatric Depression , 2001, Neuropsychopharmacology.

[18]  Jan O. Korbel,et al.  Combining frequency and positional information to predict transcription factor binding sites , 2001, Bioinform..

[19]  J. Davis,et al.  The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. , 2001, The Journal of clinical psychiatry.

[20]  DNA Arrays and Gene Expression Analysis in the Brain , 2001 .

[21]  G. Pasinetti,et al.  Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia , 2001, Journal of neuroscience research.

[22]  I. Glick,et al.  Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents , 2001, International clinical psychopharmacology.

[23]  E. Vieta,et al.  Efficacy and Safety of Risperidone in the Treatment of Schizoaffective Disorder: Initial Results From a Large, Multicenter Surveillance Study , 2001 .

[24]  R. Quirion,et al.  DNA microarrays in neuropsychopharmacology. , 2001, Trends in pharmacological sciences.

[25]  Pat Levitt,et al.  Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse , 2001, Trends in Neurosciences.

[26]  M. Webster,et al.  Application of cDNA microarrays to examine gene expression differences in schizophrenia , 2001, Brain Research Bulletin.

[27]  T. B. Ustün,et al.  Global "burden of disease"-study for psychiatric disorders. , 2001, Psychiatrische Praxis.

[28]  D. G. Standaert,et al.  Gene expression profiling in the post-mortem human brain — no cause for dismay , 2001, Journal of Chemical Neuroanatomy.

[29]  K. Mirnics,et al.  Genes and subtypes of schizophrenia. , 2001, Trends in molecular medicine.

[30]  S. Mandel,et al.  Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine , 2001, Journal of neurochemistry.

[31]  K Kosaka,et al.  Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. , 2001, Biochemical and biophysical research communications.

[32]  R. Carnahan,et al.  Ziprasidone, a New Atypical Antipsychotic Drug , 2001, Pharmacotherapy.

[33]  W. Fleischhacker,et al.  The clinical implications of weight gain in schizophrenia. , 2001, The Journal of clinical psychiatry.

[34]  Kevin G. Becker,et al.  The sharing of cDNA microarray data , 2001, Nature Reviews Neuroscience.

[35]  Daniel H. Geschwind,et al.  Sharing gene expression data: an array of options , 2001, Nature Reviews Neuroscience.

[36]  Michael F. Miles,et al.  Microarrays: lost in a storm of data? , 2001, Nature Reviews Neuroscience.

[37]  Károly Mirnics,et al.  Microarrays in brain research: the good, the bad and the ugly , 2001, Nature Reviews Neuroscience.

[38]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Ban.  Pharmacotherapy of mental illness - a historical analysis , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  S. Detera-Wadleigh.  Lithium-related genetics of bipolar disorder. , 2001, Annals of medicine.

[41]  Margaret Gardiner-Garden,et al.  A Comparison of Microarray Databases , 2001, Briefings Bioinform..

[42]  D. Lewis,et al.  Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia , 2001, Molecular Psychiatry.

[43]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Daniel H. Geschwind,et al.  Microarray Applications in Neuroscience , 2001, Neurobiology of Disease.

[45]  Jonathan Crabtree,et al.  A relational schema for both array-based and SAGE gene expression experiments , 2001, Bioinform..

[46]  K. Becker,et al.  Radioactive 33-P probes in hybridization to glass cDNA microarrays using neural tissues , 2001, Journal of Neuroscience Methods.

[47]  A. Czernik,et al.  Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique , 2001, Neuroscience Letters.

[48]  Hui Zhang,et al.  Dopaminergic cell death induced by MPP+, oxidant and specific neurotoxicants shares the common molecular mechanism , 2001, Journal of neurochemistry.

[49]  Irving L. Weissman,et al.  A Genetic Analysis of Neural Progenitor Differentiation , 2001, Neuron.

[50]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Kelsoe,et al.  Convergent functional genomics: application to bipolar disorder , 2001, Annals of medicine.

[52]  P. Levitt,et al.  DNA microarrays and human brain disorders , 2001 .

[53]  E. Vieta,et al.  Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). , 2001, The Journal of clinical psychiatry.

[54]  W. Wood,et al.  Assembly and use of a broadly applicable neural cDNA microarray. , 2001, Restorative neurology and neuroscience.

[55]  Robert C. Thompson,et al.  The “chip” as a specific genetic tool , 2000, Biological Psychiatry.

[56]  Jiasen Lu,et al.  Assessment of the sensitivity and specificity of oligonucleotide (50mer) microarrays. , 2000, Nucleic acids research.

[57]  J. Peuskens,et al.  Effects of risperidone on affective symptoms in patients with schizophrenia. , 2000 .

[58]  David A Lewis,et al.  Catching Up on Schizophrenia Natural History and Neurobiology , 2000, Neuron.

[59]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[60]  J. Trojanowski,et al.  Expression profile of transcripts in Alzheimer's disease tangle‐bearing CA1 neurons , 2000, Annals of neurology.

[61]  Rithy K. Roth,et al.  Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays , 2000, Nature Biotechnology.

[62]  W. Honer,et al.  Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. , 2000, Science.

[63]  G. Church,et al.  Microarray analysis of the transcriptional network controlled by the photoreceptor homeobox gene Crx , 2000, Current Biology.

[64]  M. Erlander,et al.  TOGA: an automated parsing technology for analyzing expression of nearly all genes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Yamada.  Induction of cysteine string protein after chronic antidepressant treatment , 2000 .

[66]  S. Mandel,et al.  cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[67]  M. Farquhar,et al.  The regulator of G protein signaling family. , 2000, Annual review of pharmacology and toxicology.

[68]  A. Jablensky.  Epidemiology of schizophrenia: the global burden of disease and disability , 2000, European Archives of Psychiatry and Clinical Neuroscience.

[69]  O. Shirakawa,et al.  Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia , 1999, Biological Psychiatry.

[70]  J. Kane.  Management strategies for the treatment of schizophrenia. , 1999, The Journal of clinical psychiatry.

[71]  R. Dufresne,et al.  Olanzapine increases weight and serum triglyceride levels. , 1999, The Journal of clinical psychiatry.

[72]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[73]  M. Farquhar,et al.  Divergence of RGS proteins: evidence for the existence of six mammalian RGS subfamilies. , 1999, Trends in biochemical sciences.

[74]  J. Pierri,et al.  Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. , 1999, The American journal of psychiatry.

[75]  Light-directed, programmable microarray synthesis , 1999, Nature Genetics.

[76]  M. Sussman,et al.  Maskless fabrication of light-directed oligonucleotide microarrays using a digital micromirror array , 1999, Nature Biotechnology.

[77]  J. Trent,et al.  Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays , 1999 .

[78]  F. Bertucci,et al.  Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. , 1999, Human molecular genetics.

[79]  T. Wetterling,et al.  Weight gain: side effect of atypical neuroleptics? , 1999, Journal of clinical psychopharmacology.

[80]  M. Farquhar,et al.  RGS proteins: more than just GAPs for heterotrimeric G proteins. , 1999 .

[81]  M. Brecher,et al.  A combined analysis of double‐blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms , 1999, Acta psychiatrica Scandinavica.

[82]  J. Weingarten,et al.  Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques , 1999, Annals of neurology.

[83]  D. Pappin,et al.  The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis — Preliminary findings , 1999, Electrophoresis.

[84]  D. Botstein,et al.  Exploring the new world of the genome with DNA microarrays , 1999, Nature Genetics.

[85]  M. Morley,et al.  Making and reading microarrays , 1999, Nature Genetics.

[86]  M. Bittner,et al.  Expression profiling using cDNA microarrays , 1999, Nature Genetics.

[87]  M. Jackson,et al.  Gene expression profiles of laser-captured adjacent neuronal subtypes , 1999, Nature Medicine.

[88]  E. Southern,et al.  Molecular interactions on microarrays , 1999, Nature Genetics.

[89]  S. P. Fodor,et al.  High density synthetic oligonucleotide arrays , 1999, Nature Genetics.

[90]  J. Peuskens,et al.  Effects of risperidone on affective symptoms in patients with schizophrenia , 1998, European Neuropsychopharmacology.

[91]  S. Marder,et al.  Novel antipsychotics and new onset diabetes , 1998, Biological Psychiatry.

[92]  H. Meltzer,et al.  Selective Increases in Phosphoinositide Signaling Activity and G Protein Levels in Postmortem Brain from Subjects with Schizophrenia or Alcohol Dependence , 1998, Journal of neurochemistry.

[93]  W. Fleischhacker,et al.  Weight gain induced by olanzapine , 1998, Schizophrenia Research.

[94]  D. Geschwind,et al.  Klinefelter's syndrome as a model of anomalous cerebral laterality: testing gene dosage in the X chromosome pseudoautosomal region using a DNA microarray. , 1998, Developmental genetics.

[95]  José L. Ayuso-Gutiérrez,et al.  Factors influencing relapse in the long-term course of schizophrenia , 1997, Schizophrenia Research.

[96]  S. Marder,et al.  The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. , 1997, The Journal of clinical psychiatry.

[97]  L. Wodicka,et al.  Genome-wide expression monitoring in Saccharomyces cerevisiae , 1997, Nature Biotechnology.

[98]  P. Brown,et al.  Exploring the metabolic and genetic control of gene expression on a genomic scale. , 1997, Science.

[99]  E. Nestler,et al.  Regulators of G-Protein Signaling (RGS) Proteins: Region-Specific Expression of Nine Subtypes in Rat Brain , 1997, The Journal of Neuroscience.

[100]  M. Nakaya,et al.  Depressive symptoms in acute schizophrenic inpatients , 1997, Schizophrenia Research.

[101]  P. Czobor,et al.  Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes , 1997, Psychiatry Research.

[102]  R. W. Davis,et al.  Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[103]  L. Liotta,et al.  Laser Capture Microdissection , 1996, Science.

[104]  David J. King,et al.  Cognitive Functioning in Schizophrenia , 1996 .

[105]  A. Gilman,et al.  The GTPase-activating Protein RGS4 Stabilizes the Transition State for Nucleotide Hydrolysis* , 1996, The Journal of Biological Chemistry.

[106]  P. Brown,et al.  Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[107]  A. Gilman,et al.  GAIP and RGS4 Are GTPase-Activating Proteins for the Gi Subfamily of G Protein α Subunits , 1996, Cell.

[108]  N. Shen,et al.  Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.

[109]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[110]  D. Lockhart,et al.  Expression monitoring by hybridization to high-density oligonucleotide arrays , 1996, Nature Biotechnology.

[111]  R. Baldessarini.  Drugs and the treatment of psychiatric disorders , 1996 .

[112]  A. Gilman,et al.  GAIP and RGS4 are GTPase-activating proteins for the Gi subfamily of G protein alpha subunits. , 1996, Cell.

[113]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[114]  W. Fleischhacker,et al.  Weight gain induced by clozapine , 1995, European Neuropsychopharmacology.

[115]  Paul J. Harrison,et al.  The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins , 1995, Neuroscience Letters.

[116]  Azorin Jm.  Long-term treatment of mood disorders in schizophrenia. , 1995 .

[117]  J. Azorin.  Long‐term treatment of mood disorders in schizophrenia , 1995, Acta psychiatrica Scandinavica. Supplementum.

[118]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[119]  Y Sakaki,et al.  High-density cDNA filter analysis: a novel approach for large-scale, quantitative analysis of gene expression. , 1995, Gene.

[120]  W. Carpenter,et al.  Domains of Psychopathology: An Approach to the Reduction of Heterogeneity in Schizophrenia , 1994, The Journal of nervous and mental disease.

[121]  E. W. Hutchinson,et al.  A method for analysis of gene expression patterns. , 1994, Analytical biochemistry.

[122]  Paul J. Harrison,et al.  Pre‐and Postmortem Influences on Brain RNA , 1993, Journal of neurochemistry.

[123]  O. Shirakawa,et al.  Increase in [3H]cAMP binding sites and decrease in Giα and Goα immunoreactivities in left temporal cortices from patients with schizophrenia , 1993, Brain Research.

[124]  O. Shirakawa,et al.  Increase in [3H]cAMP binding sites and decrease in Gi alpha and Go alpha immunoreactivities in left temporal cortices from patients with schizophrenia. , 1993, Brain research.

[125]  K. Nave,et al.  Uncoupling of hypomyelination and glial cell death by a mutation in the proteolipid protein gene , 1992, Nature.

[126]  R. Drmanac,et al.  Sequencing of megabase plus DNA by hybridization: theory of the method. , 1989, Genomics.

[127]  F. Bloom,et al.  Splice site selection in the proteolipid protein (PLP) gene transcript and primary structure of the DM-20 protein of central nervous system myelin. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[128]  C. Kozak,et al.  Aberrant splicing of proteolipid protein mRNA in the dysmyelinating jimpy mutant mouse. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[129]  F. Bloom,et al.  Jimpy mutant mouse: a 74-base deletion in the mRNA for myelin proteolipid protein and evidence for a primary defect in RNA splicing. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[130]  T. Powell,et al.  An electron microscopic study of the types and proportions of neurons in the cortex of the motor and visual areas of the cat and rat. , 1980, Brain : a journal of neurology.